Myocardial Calcium Handling in Type 2 Diabetes: A Novel Therapeutic Target

被引:1
|
作者
Dattani, Abhishek [1 ]
Singh, Anvesha
Mccann, Gerry P.
Gulsin, Gaurav S.
机构
[1] Univ Leicester, Dept Cardiovasc Sci, Leicester LE3 9QP, England
关键词
diabetes; calcium handling; manganese-enhanced MRI; GLYCATION END-PRODUCTS; SARCOPLASMIC-RETICULUM CA2+-ATPASE; CONGESTIVE-HEART-FAILURE; DIASTOLIC DYSFUNCTION; VENTRICULAR MYOCYTES; CARDIAC STRUCTURE; GENE-EXPRESSION; MANGANESE IONS; YOUNG-ADULTS; CARDIOMYOPATHY;
D O I
10.3390/jcdd11010012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes (T2D) is a multisystem disease with rapidly increasing global prevalence. Heart failure has emerged as a major complication of T2D. Dysregulated myocardial calcium handling is evident in the failing heart and this may be a key driver of cardiomyopathy in T2D, but until recently this has only been demonstrated in animal models. In this review, we describe the physiological concepts behind calcium handling within the cardiomyocyte and the application of novel imaging techniques for the quantification of myocardial calcium uptake. We take an in-depth look at the evidence for the impairment of calcium handling in T2D using pre-clinical models as well as in vivo studies, following which we discuss potential novel therapeutic approaches targeting dysregulated myocardial calcium handling in T2D.
引用
收藏
页数:19
相关论文
共 50 条
  • [1] The vascular smooth muscle cell: a therapeutic target in Type 2 diabetes?
    Porter, Karen E.
    Riches, Kirsten
    CLINICAL SCIENCE, 2013, 125 (3-4) : 167 - 182
  • [2] The adiponectin signalling pathway - A therapeutic target for the cardiac complications of type 2 diabetes?
    Sharma, Abhipree
    Mah, Michael
    Ritchie, Rebecca H.
    De Blasio, Miles J.
    PHARMACOLOGY & THERAPEUTICS, 2022, 232
  • [3] PGC-1 activation: a therapeutic target for type 2 diabetes?
    Yuan, Daixiu
    Xiao, Dingfu
    Gao, Qian
    Zeng, Liming
    EATING AND WEIGHT DISORDERS-STUDIES ON ANOREXIA BULIMIA AND OBESITY, 2019, 24 (03) : 385 - 395
  • [4] Echocardiographic assessment of myocardial function in patients with type 2 diabetes
    Gac, Pawel
    Poreba, Rafal
    Zawadzki, Marcin
    Roemer, Roma
    Pawlas, Krystyna
    Andrzejak, Ryszard
    Szuba, Andrzej
    ENDOKRYNOLOGIA POLSKA, 2009, 60 (04) : 277 - 286
  • [5] Molecular therapeutic target for type-2 diabetes
    Chou, KC
    JOURNAL OF PROTEOME RESEARCH, 2004, 3 (06) : 1284 - 1288
  • [6] AMPK activation: a therapeutic target for type 2 diabetes?
    Coughlan, Kimberly A.
    Valentine, Rudy J.
    Ruderman, Neil B.
    Saha, Asish K.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2014, 7 : 241 - 253
  • [7] VNUT Is a Therapeutic Target for Type 2 Diabetes and NASH
    Hasuzawa, Nao
    Tatsushima, Keita
    Tokubuchi, Rie
    Kabashima, Masaharu
    Nomura, Masatoshi
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2021, 141 (04): : 517 - 526
  • [8] eNAMPT is a novel therapeutic target for mitigation of coronary microvascular disease in type 2 diabetes
    Gao, Lei
    Ramirez, Francisco J.
    Cabrera, Jody Tori O.
    Varghese, Mathews V.
    Watanabe, Makiko
    Tsuji-Hosokawa, Atsumi
    Zheng, Qiuyu
    Yang, Mingya
    Razan, Md Rahatullah
    Kempf, Carrie L.
    Camp, Sara M.
    Wang, Jian
    Garcia, Joe G. N.
    Makino, Ayako
    DIABETOLOGIA, 2024, 67 (09) : 1998 - 2011
  • [9] Metabolic control of myofibers: promising therapeutic target for obesity and type 2 diabetes
    Duan, Yehui
    Li, Fengna
    Tan, Bie
    Yao, Kang
    Yin, Yulong
    OBESITY REVIEWS, 2017, 18 (06) : 647 - 659
  • [10] Cardiac Autoimmunity as a Novel Biomarker, Mediator, and Therapeutic Target of Heart Disease in Type 1 Diabetes
    Lipes, Myra A.
    Galderisi, Alfonso
    CURRENT DIABETES REPORTS, 2015, 15 (05)